The first two authors contributed equally to this work It has been suggested that H. pylori infection upregulates iNOS expresion and synthesis of nitric oxide (NO). In order to extend the scope, exhaled NO in H. pylori-infected patients with chronic gastritis was investigated. Exhaled oral NO level was measured with Niox Mino" analyzer, twice before and six-seven months after successful H. pylori eradication therapy in 26 patients with gastritis and in 16 healthy non-atopic subjects. Exhaled NO was significantly increased in H. pylori-infected patients with chronic gastritis as compared with the healthy subjects. Following eradication the levels were significantly reduced compared to the basal level before the therapy and did not differ significantly from those of the healthy subjects. It seems that H. pylori-associated gastritis is accompanied by an increased level of exhaled NO, resulting probably from the locally increased NO production.
Nitric oxide (NO) is generated through conversion of L-arginine into L-citrulline by NO synthases (NOS). Various proinflammatory mediators and lipopolysaccharides are capable ofinducing inducible NOS (iNOS) expression (1). It has been indicated that H. Pylori infection upregulates NO synthesis in local tissues (2) . In addition, it has been suggested that in patients with H. pylori-positive gastritis, NO and other reactive nitrogen species generated by iNOS may modulate a local inflammatory response (3) .
Exhaled NO is produced in a large amount during asthmatic airway inflammation and can be a sensitive yet not a specific marker of the disease (1, 4) . The level of exhaled NO is increased in numerous other diseases, including bronchiectasis (5) chronic tonsillitis (6) , infections of upper respiratory tract (7) , but not in glottic carcinoma (8) . Identification of all NO sources which influence the exhaled levels of NO are important in clinical practice, where NO measurement is frequently used in diagnosis and monitoring of asthma.
Apart from sinuses, NO production was found in the gastrointestinal tract resulting from various exogenous and endogenous stimulants, including dietary and bacterial factors (9) . It has been suggested that H. pylori infection reduces NO level in the gastric lumen (10) , but increases the levels of NO metabolites in gastric juice (1O, II), serum (12) and in exhaled air (13) . To date, it is unknown how the infection affects NO level (directly, not its metabolites) in exhaled air. In order to extend previous observations and to determine the effect of eradication therapy on NO level, in the current study exhaled oral NO was measured twice: before and after successful H. pylori eradication therapy in patients with gastritis and in healthy non-atopic subjects.
MATERIALS AND METHODS
The study comprised twenty-six non-atopic, nonsmoking H. pylori-infected patients (II women, 15 men; median age 39 years, range 21-61 years) with chronic active gastritis assessed according to Sydney system (14) (grade I or 2) -H. pylori positive (+) period. In the same group, exhaled oral NO was examined again 6-7 months after successful H. pylori therapy -H. pylori negative (-) period. Patients were treated with triple anti-H. pylori therapy (amoxicillin, 1000 mg b.i.d; metronidazole, 500 mg b.i.d.; and omeprasole 20 mg b.i.d.) for 7 days.
During the first examination, H. pylori infection was detected with fast urea test (CLO-test), then confirmed by biopsy. During the second endoscopic examination the patients showed no inflammatory changes and proved H. pylori negative (negative CLO-test).
The specific exclusion criteria comprised known diseases and other factors which may affect exhaled NO concentration, including asthma, rhinitis, sinusitis and carries. Routine allergological, dental and laryngological examinations were performed.
The control group comprised 16 non-atopic, nonsmoking subjects (10 women, 6 men; median age 41 years, range 18-61) with endoscopically normal gastroduodenal mucosa and H. pylori infection negative (negative ClOtest), who underwent gastroscopy because of dyspepsia.
The study design was approved by the Ethics Committee (KNW/0022/KBI/30/I/II) and an informed consent was obtained from each of the subjects.
Measurement ofexhaled nitric oxide
Exhaled oral NO levels were measured in duplicate using Niox Mino" analyzer (Aerocrine AB, Solna, Sweden). NO level is expressed in parts per billion (ppb).
Statistical analysis
The levels of exhaled nitric oxide were compared between patients and the healthy controls using Mann-Whitney test. For comparisons in the same individuals over the time, Wilcoxon matched pairs test was used. Data are presented as median and inter-quartile range. P values below 0.05 were considered significant. compared with the healthy subjects (median and inter-quartile range: 26.9 (21.0-31.0) vs 13.7 (12) (13) (14) ppb; p<O.OI (Fig. 1) . Following eradication, the levels were significantly reduced as compared to the basal level before the therapy and did not differ significantly from those of the healthy subjects (median value and inter-quartile range: 26.9 (21.0-31.0), 15.04 (10.0-19.0) and 13.7 (12.0-14.0) ppb, respectively; p<O.O 1) ( Fig. 1) .
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Up-regulated iNOS expression and NO overproduction have been demonstrated in human gastric epithelial cell lines in response to H. pylori infection (14) . H. pylori has a potent ability to stimulate NO synthesis in macrophages and neutrophils, suggesting that H. pylori infection might induce an endogenous formation of NO (2) . Locally produced NO may possibly be transferred into nitrites and nitrates by oxidation, which results into elevated levels in H. pylori-infected patients (15) . The increased levels of NO metabolites in the gastric juice (11), serum (12) and in the exhaled air of H. pylori-infected patients (13) have been reported. In addition, effective anti-H. pylori therapy reduces NO metabolite concentration in the gastric juice (11).
In our study, exhaled NO was significantly increased in H. pylori-infected patients with chronic gastritis, compared to the healthy subjects. After eradication the levels were significantly reduced compared to the basal level before therapy and did not differ significantly from those of the healthy subjects. Contrary to our results, H. pylori-positive patients had a significantly lower NO concentration in the gastric lumen and higher nitrite levels in the gastric juice (10) . The intraluminal concentration of NO in H. pylori-positive patients was markedly increased and the concentration ofnitrite in H. pyloripositive patients was markedly decreased following the completion of eradication therapy, suggesting that H. pylori may reduce intraluminal production of NO by promoting the conversion from NO to nitrite (10) . This process may be mediated by different factors including superoxide anion (10) .
Taken together, the results indicate that we should theoretically expect decreased NO concentration in the exhaled airway and increased values after the eradication. The discrepancy ofthe results is unclear. We investigated NO in exhaled air of patients with gastritis while Shiotani et al. (10) characterized patients only as H. pylori-positive ornegative without information regarding the grade of the inflammatory state in the stomach. We can only speculate that the inflammatory state (chronic active gastritis grade 1 and 2) induced by the infection, not HP-infection alone, influenced enhanced NO production, resulting in the increased exhaled NO concentration in our patients. To clarify this problem further studies in the area are needed.
On the other hand, it has been observed that esophagitis, also with concomitant chronic gastritis, does not influence exhaled NO concentration. However, only a limited number of patients has been infected with H. pylori (15.7%) (16) .
Some limitations regarding this study should be taken into consideration. Firstly, the relatively small number of patients could appear as a potential drawback. Secondly, we did not determine any association between the levels of exhaled NO in gastritis patients or the grade of inflammatory lesions in gastric mucosa, which was due to the small sample size and only mild/moderate grades of the inflammatory lesions. Interestingly, in previous studies it was demonstrated that the increase of NO metabolite concentration in gastric juice demonstrates positive correlation with the grade of inflammatory lesions in gastric mucosa (11). Thirdly, we did not investigate any patients with H. pylori infection and without concomitant gastritis.
The results of the present study indicate that the levels of exhaled NO are elevated in H. pyloriinfected patients with chronic gastritis. It seems, that H. pylori-associated gastritis is accompanied by the increased level of exhaled NO. Very interesting and clinically relevant, the observation emphasizes consideration of that disease as a factor which could influence the NO records upon diagnostics and while treating other concurrent diseases, e.g. bronchial asthma. Identification all sources of NO which infuence exhaled levels of NO proves crucial for proper diagnostic and therapeutic decisions.
